21.218 articles found

Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys.

Goulet M, Grondin R, Blanchet PJ, Bédard PJ, Di Paolo T.

Brain Res · 1996-05-01

DOI: 10.1016/0006-8993(96)00157-6PMID: 8782872

Nicotinic receptors in the brain. Molecular biology, function, and therapeutics.

Vidal C.

Mol Chem Neuropathol · 1996-05-01

DOI: 10.1007/bf02815199PMID: 8871936

BENZAMIDES AS MEDICAMENT FOR TREATMENT OF NEURODEGENERATIVE STATE, A METHOD FOR THE PREPARATION THEREOF (VARIANTS), PHARNACEUTICAL COMPOSITION FOR TREATMENT OF NEURODEGENERATIVE STATES AND A METHOD FOR TREATMENT

Check source for author details

· 1996-04-03

Toward trophic treatment in parkinsonism: a primate step.

Olson L.

Nat Med · 1996-04-01

DOI: 10.1038/nm0496-400PMID: 8597946

A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia.

Lohr JB, Caligiuri MP.

J Clin Psychiatry · 1996-04-01

PMID: 8601552

The effects of co-administration of benzhexol on the peripheral pharmacokinetics of oral levodopa in young volunteers.

Roberts J, Waller DG, von Renwick AG, O'Shea N, Macklin BS, Bulling M.

Br J Clin Pharmacol · 1996-04-01

DOI: 10.1046/j.1365-2125.1996.32311.xPMID: 8730980

Basal ganglia: new therapeutic approaches to Parkinson's disease.

Graybiel AM.

Curr Biol · 1996-04-01

DOI: 10.1016/s0960-9822(02)00497-9PMID: 8723334

[New vistas in the treatment of Parkinson disease].

Kobayashi T.

Nihon Ronen Igakkai Zasshi · 1996-04-01

PMID: 8752711

A controlled study of facial mobility treatment in Parkinson's disease.

Katsikitis M, Pilowsky I.

J Psychosom Res · 1996-04-01

DOI: 10.1016/0022-3999(95)00611-7PMID: 8736419

Rate of motor response to oral levodopa and the clinical progression of Parkinson's disease.

Contin M, Riva R, Martinelli P, Triggs EJ, Albani F, Baruzzi A.

Neurology · 1996-04-01

DOI: 10.1212/wnl.46.4.1055PMID: 8780090

Early morning akinesia in Parkinson's disease: effect of standard carbidopa/levodopa and sustained-release carbidopa/levodopa.

Pahwa R, Lyons K, McGuire D, Dubinsky R, Hubble JP, Koller WC.

Neurology · 1996-04-01

DOI: 10.1212/wnl.46.4.1059PMID: 8780091

Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease.

Hutton JT, Koller WC, Ahlskog JE, Pahwa R, Hurtig HI, Stern MB, Hiner BC, Lieberman A, Pfeiffer RF, Rodnitzky RL, Waters CH, Muenter MD, Adler CH, Morris JL.

Neurology · 1996-04-01

DOI: 10.1212/wnl.46.4.1062PMID: 8780092